IL-5 inhibitors lead to dramatic reductions in eosinophil levels within 3 days in five patients with drug reaction with eosinophilia and systemic symptoms (DRESS).
TOPLINE: A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with eosinophilia and systemic symptoms (DRESS), with no adverse events or long-term autoimmune sequelae. METHODOLOGY: Researchers conducted a retrospective case series of 16 patients treated with IL-5 inhibitors across the Mass General Brigham system, of whom five (two women, five men) met criteria for possible DRESS (Registry of Severe Cutaneous Adverse Reactions score ≥ 3). The mean peak absolute eosinophil count was 5200 (range, 1800-10,000) cells/μL. The patients required IL-5 inhibitors (mepolizumab or benralizumab) because of contraindications to or failure of oral,…